Adeona Pharmaceuticals, Inc., a development-stage specialty pharmaceutical company, focuses on the awareness, diagnosis, prevention, and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature population. Such conditions may contribute to the progression of debilitating degenerative diseases, including, dry age-related macular degeneration, Alzheimer’s disease, and mild cognitive impairment in susceptible persons. The company also engages in developing proprietary late-stage drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis. Its principal products in clinical development include Oral dnaJP1 for the induction of immune tolerance in rheumatoid arthritis; TRIMESTA, an oral immunomodulatory and anti-inflammatory bio-identical estrogenic agent in Phase IIb clinical trial for the treatment of post-menopausal hot flashes; and Oral Flupirtine, a non-opiate non-addictive oral therapy for the treatment of fibromyalgia and other ophthalmic indications. The company was founded in 2001 and is based in Ann Arbor, Michigan.
http://www.adeonapharma.com
Etiketler: Adeona, Adeona Pharmaceuticals, Adeona Pharmaceuticals Inc., AMEX:AEN, Biotechnology, CD4 Inhibitors, Coprexa, Effirma, Flupirtine, healthcare, Oral dnaJP1, Oral TTM, Oral ZMC, Pharmaceutical, Scientific References, Trimesta, Zinthionein
